RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $22.99 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.